{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:30:30Z","timestamp":1777480230238,"version":"3.51.4"},"reference-count":35,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"General Program of National Natural Science Foundation of China","award":["72174207"],"award-info":[{"award-number":["72174207"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>The Chinese community-acquired pneumonia (CAP) Diagnosis and Treatment Guideline 2020 recommends quinolone antibiotics as the initial empirical treatment options for CAP. However, patients with pulmonary tuberculosis (PTB) are often misdiagnosed with CAP because of the similarity of symptoms. Moxifloxacin and levofloxacin have inhibitory effects on mycobacterium tuberculosis as compared with nemonoxacin, resulting in delayed diagnosis of PTB. Hence, the aim of this study is to compare the cost-effectiveness of nemonoxacin, moxifloxacin and levofloxacin in the treatment of CAP and to determine the value of these treatments in the differential diagnosis of PTB. Primary efficacy data were collected from phase II-III randomized, double-blind, multi-center clinical trials comparing nemonoxacin to moxifloxacin (CTR20130195) and nemonoxacin to levofloxacin (CTR20140439) for the treatment of Chinese CAP patients. A decision tree was constructed to compare the cost-utility among three groups under the perspective of healthcare system. The threshold for willingness to pay (WTP) is 1\u20133 times GDP per capita ($11,174\u201333,521). Scenarios including efficacy and cost for CAP patients with a total of 6% undifferentiated PTB. Sensitivity and scenario analyses were performed to test the robustness of basic analysis. The costs of nemonoxacin, moxifloxacin, and levofloxacin were $903.72, $1053.59, and $1212.06 and the outcomes were 188.7, 188.8, and 188.5 quality-adjusted life days (QALD), respectively. Nemonoxacin and moxifloxacin were dominant compared with levofloxacin, and the ICER of moxifloxacin compared with nemonoxacin was $551,643, which was much greater than WTP; therefore, nemonoxacin was the most cost-effective option. Regarding patients with PTB who were misdiagnosed with CAP, taking nemonoxacin could save $290.76 and $205.51 when compared with moxifloxacin and levofloxacin and resulted in a gain of 2.83 QALDs. Our findings demonstrate that nemonoxacin is the more economical compared with moxifloxacin and levofloxacin, and non-fluoroquinolone antibiotics are cost-saving and utility-increasing compared to fluoroquinolones in the differential diagnosis of PTB, which can help healthcare system in making optimal policies and help clinicians in the medication of patients.<\/jats:p>","DOI":"10.3390\/ijerph19084816","type":"journal-article","created":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T07:42:41Z","timestamp":1650094961000},"page":"4816","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis"],"prefix":"10.3390","volume":"19","author":[{"given":"Mingye","family":"Zhao","sequence":"first","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, China"},{"name":"Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoyuan","family":"Chi","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, China"},{"name":"Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingming","family":"Pan","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, China"},{"name":"Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Yin","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, China"},{"name":"Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3564-3626","authenticated-orcid":false,"given":"Wenxi","family":"Tang","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, China"},{"name":"Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"ref_1","unstructured":"Respiratory Medicine Branch of Chinese Medical Association (2016). Guidelines for the diagnosis and treatment of community-acquired pneumonia in Chinese adults. Chin. J. Tuberc. Respir. Med., 39, 253\u2013279."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2010","journal-title":"Thorax"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1056\/NEJMoa1405870","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. children","volume":"372","author":"Jain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.7883\/yoken.67.269","article-title":"High Incidence of Community-Acquired Pneumonia among Rapidly Aging Population in Japan: A Prospective Hospital-Based Surveillance","volume":"67","author":"Takaki","year":"2014","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1016\/j.vaccine.2020.11.004","article-title":"Incidence of community-acquired pneumonia in urban China: A national population-based study","volume":"38","author":"Sun","year":"2020","journal-title":"Vaccine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejim.2018.10.020","article-title":"An international perspective on hospitalized patients with viral community-acquired pneumonia","volume":"60","author":"Radovanovic","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults","volume":"373","author":"Jain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","first-page":"1178","article-title":"Value of combined detection of PCT, WBC, and Th1\/Th2 in the differential diagnosis of early community\u2014Acquired pneumonia and tuberculosis","volume":"20","author":"Yunjing","year":"2021","journal-title":"J. Clin. Exp. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2666-5247(21)00301-3","article-title":"The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: A genotypic analysis","volume":"3","author":"Walker","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijantimicag.2007.09.014","article-title":"Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: A prospective study by the Asian network for surveillance of resistant pathogens","volume":"31","author":"Song","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_12","first-page":"261","article-title":"Effect of fluoroquinolone treatment on the diagnosis of pulmonary tuberculosis:clinical analysis of 103cases of tuberculosis misdiagnosed as community-acquired pneumonia","volume":"13","author":"Qiu","year":"2013","journal-title":"Chin. J. Infect. Chemother."},{"key":"ref_13","first-page":"155","article-title":"Should fluoroquanolones be the first-line empirical antibiotics in the treatment of community-acquired pneumonia in China: Right or not?","volume":"3","author":"Wenjie","year":"2010","journal-title":"Chin. J. Lung Dis."},{"key":"ref_14","first-page":"663","article-title":"Nemonoxacin: A novel nonfluorinated quinolone antibiotic","volume":"18","author":"Min","year":"2018","journal-title":"Chin. J. Infect. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5588\/ijtld.20.0513","article-title":"A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB","volume":"25","author":"Tweed","year":"2021","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"102056","DOI":"10.1016\/j.pupt.2021.102056","article-title":"Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial","volume":"70","author":"Laohapojanart","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1086\/498520","article-title":"Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): Efficacy and Safety of Moxifloxacin Therapy versus That of Levofloxacin Therapy","volume":"42","author":"Anzueto","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.chest.2018.11.001","article-title":"The Cost-Effectiveness of Corticosteroids for the Treatment of Community-Acquired Pneumonia","volume":"155","author":"Pliakos","year":"2019","journal-title":"Chest"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1524-4733.2009.00576.x","article-title":"Comparative Analysis of Length of Stay, Total Costs, and Treatment Success between Intravenous Moxifloxacin 400 mg and Levofloxacin 750 mg among Hospitalized Patients with Community-Acquired Pneumonia","volume":"12","author":"Friedman","year":"2009","journal-title":"Value Health"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e018709","DOI":"10.1136\/bmjopen-2017-018709","article-title":"Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: A retrospective multicentre survey","volume":"8","author":"Chen","year":"2018","journal-title":"BMJ Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1086\/587519","article-title":"Moxifloxacin Monotherapy Is Effective in Hospitalized Patients with Community-Acquired Pneumonia: The MOTIV Study\u2014A Randomized Clinical Trial","volume":"46","author":"Torres","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"658.e1","DOI":"10.1016\/j.cmi.2017.09.014","article-title":"Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals","volume":"24","author":"Nie","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.clinthera.2021.03.006","article-title":"Clinical Benefits and Cost-Effectiveness of Moxifloxacin as Initial Treatment for Community-Acquired Pneumonia: A Meta-Analysis and Economic Evaluation","volume":"43","author":"Du","year":"2021","journal-title":"Clin. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s10096-016-2890-7","article-title":"Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients","volume":"36","author":"Voruganti","year":"2017","journal-title":"Eur. J. Clin. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ijid.2021.10.029","article-title":"Cost-effectiveness of video-observed therapy for ambulatory management of active tuberculosis during the COVID-19 pandemic in a high-income country","volume":"113","author":"Fekadu","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13063-018-2608-5","article-title":"Shorter treatment for minimal tuberculosis (TB) in children (SHINE): A study protocol for a randomised controlled trial","volume":"19","author":"Chabala","year":"2018","journal-title":"Trials"},{"key":"ref_27","unstructured":"Chinese Medical Association (2019). Guidelines for primary care of pulmonary tuberculosis (2018). Chin. J. Gen. Pract., 18, 709\u2013717."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Machlaurin, A., Dolk, F.C.K., Setiawan, D., Van Der Werf, T.S., and Postma, M.J. (2020). Cost-Effectiveness Analysis of BCG Vaccination against Tuberculosis in Indonesia: A Model-Based Study. Vaccines, 8.","DOI":"10.3390\/vaccines8040707"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0002-9343(00)00591-X","article-title":"Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome","volume":"109","author":"Hamel","year":"2000","journal-title":"Am. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Egger, M.E., Myers, J.A., Arnold, F.W., Pass, L.A., Ramirez, J.A., and Brock, G.N. (2016). Cost effectiveness of adherence to IDSA\/ATS guidelines in elderly patients hospitalized for Community-Aquired Pneumonia. BMC Med. Inform. Decis. Mak., 16.","DOI":"10.1186\/s12911-016-0270-y"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e050629","DOI":"10.1136\/bmjopen-2021-050629","article-title":"Cross-sectional study of prevalence and risk factors, and a cost-effectiveness evaluation of screening and preventive treatment strategies for latent tuberculosis among migrants in Singapore","volume":"11","author":"Lim","year":"2021","journal-title":"BMJ Open"},{"key":"ref_32","unstructured":"Guoen, L. (2020). Chinese Guidelines for Pharmacoeconomics Evaluation 2020, China Market Press."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1185\/030079908X280400","article-title":"A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: Results from the MOTIV trial","volume":"24","author":"Lloyd","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"ofab476","DOI":"10.1093\/ofid\/ofab476","article-title":"The Cost-effectiveness of Cefazolin Compared with Antistaphylococcal Penicillins for the Treatment of Methicillin-Sensitive Staphylococcus aureus Bacteremia","volume":"8","author":"Pliakos","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"van Werkhoven, C.H., Postma, D.F., Mangen, M.J., Oosterheert, J.J., and Bonten, M.J. (2017). Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: Results from a cluster randomized cross-over trial. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-016-2179-6"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/8\/4816\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:54:45Z","timestamp":1760136885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/8\/4816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["ijerph19084816"],"URL":"https:\/\/doi.org\/10.3390\/ijerph19084816","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]}}}